Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Target to B-cure

Financiado

Targeting auto reactive B cells by vaccination to cure human auto immune disease

Currently, most human autoimmune diseases are chronic conditions without a prospect of cure. My aim in this proposal is to meet the next major challenge, achieving cure in autoimmune disease. Many autoimmune diseases are characte... ver más

31/12/2025

Leiden University...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-06-19

ERC-2019-ADG: ERC Advanced Grant

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

Leiden University Medical Ce...

2.50M€ | Lider

CM4 ENGINYERIA

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-128244OB-I00 REDES DE MICRORNAS REGULADORAS EN TOLERANCIA DE CELULAS B Y... 345K€ Cerrado

BCELLMECHANICS Regulation of antibody responses by B cell mechanical activi... 2M€ Cerrado

PDC2022-133701-I00 INFLAMACION TERAPIAS VIRALES 150K€ Cerrado

SAF2011-23639 MECANISMOS MOLECULARES Y CELULARES QUE OPERAN EN LAS ENFERME... 230K€ Cerrado

SAF2015-66399-R PRESENTACION DE AUTOANTIGENOS PROTEICOS Y LIPIDICOS EN LOS I... 303K€ Cerrado

SAF2012-33218 REGULACION DINAMICA DE LA SEÑALIZACION POR CITOCINAS EN LINF... 105K€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2020-06-19
Fecha Fin: 2025-12-31

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Currently, most human autoimmune diseases are chronic conditions without a prospect of cure. My aim in this proposal is to meet the next major challenge, achieving cure in autoimmune disease. Many autoimmune diseases are characterized by autoantibodies and are remarkably responsive to B-cell targeted therapies, demonstrating that the autoreactive B-cell is central to disease pathogenesis. Nonetheless, the selective and permanent elimination of the autoreactive B-cell, both memory and plasma cells alike, is not presently feasible due to a lack of specific markers and treatments. My aim is to develop a vaccine that will allow the specific and long-lasting depletion of autoreactive B-cells, thereby inducing cure. Using the unique mutated sequences of autoreactive B-cell receptors (BCR), cytotoxic T-cells that specifically eradicate autoreactive B-cells will be induced. This concept extends the remit of vaccines beyond infectious diseases and cancer, into the sphere of autoimmune disease. Using the well-defined autoimmune disease rheumatoid arthritis (RA) as prototype, I will study the RA-specific autoimmune response. Our recent findings show that RA is characterized by a restricted, oligoclonally-expanded autoreactive B-cell pool. Using recently developed technologies, my team will identify autoreactive B-cells and the BCR repertoire at several (pre)disease stages. We will then determine the potency of the many non-germline-encoded mutations in BCRs as neoantigens amenable to T-cell recognition and vaccination. Incorporating these neoantigens into multiple long peptides covering the autoreactive B-cell repertoire, we will design patient-tailored vaccines and perform a phase I trial to determine the feasibility of specifically depleting disease-causing B-cells. This research will create the possibility for patient-tailored vaccines that can permanently eradicate auto-reactive B-cells in B-cell driven auto-immune diseases; diseases that are still incurable to date.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores